New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell ...
Allied Gold Corporation (TSX: AAUC, NYSE: AAUC) (“Allied” or the “Company”) provides its preliminary operating results for the third quarter ending September 30, 2025. The Company produced over 87,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback